Plain-English translation of NCT07340489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for locally advanced cervical cancer using a combination of three therapies: (an immunotherapy drug), , and radiation. Half of the participants will receive immunotherapy plus radiation, while the other half will receive the same treatments plus additional before and after. Researchers want to see if adding more helps patients live longer without their cancer growing.
Currently, standard treatment for advanced cervical cancer combines with radiation, but outcomes are not perfect for all patients. This trial is testing whether this medication—which helps the immune system fight cancer—combined with and radiation can improve how well the treatment works.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two treatment groups. Both groups will receive immunotherapy combined with and radiation therapy. The other group will receive additional cycles before and after the combined treatment. You will receive maintenance immunotherapy for up to 2 years after your initial treatment. The trial will track how well your cancer responds, check for side effects, and measure how long you survive without your cancer progressing.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China